Preserving Quality of Life in PV


Dr. Kuykendall discusses the important quality of life aspects to consider when treating PV patients and the specific strategies or treatments he uses to help preserve overall QoL throughout the disease course.

Case: Management of Advanced Polycythemia Vera in a 67-Year-Old-Male

Clinical Presentation:

  • 67-year-old male presented with frequent headache and dizziness
  • Prior medical history is notable for smoking.
  • PMH: unremarkable, no splenomegaly

Initial Clinical Workup and Diagnosis:

  • Labs:
    • Hemoglobin, 20.5 g/dL
    • White blood cell count, 13 K/L
    • Platelet count, 380 K/L
    • Hematocrit, 68%
  • JAK2-V617F mutation- variant allele frequency of 65%
  • Bone marrow biopsy: trilineage proliferation and pleiomorphic megakaryocytes
  • The patient started phlebotomy, aspirin, and Hydroxyurea (HU)

Initial Treatments:

  • The patient started phlebotomy, aspirin and HU.
    • Over the next year the patient underwent several phlebotomies and remained on aspirin and 2000 mg/day of HU

Disease Progression and Subsequent Treatments:

February 2019

  • 2 phlebotomies since the last visit 3 months earlier
  • He is also experiencing fatigue and night sweats.
  • Labs
    • Hgb, 15.5 g/dL
    • WBC, 13 K/L
    • Platelet count, 380 K/L
    • Hematocrit, 47%
Related Videos
Video 8 - "Clinical Pearls for Optimal Management of mHSPC"
Video 7 - "Multidisciplinary Approach in mHSPC Management "
Video 6 - "Treatment Considerations in High Disease Burden and Comorbidities"
Video 5 - "Pivotal Trials in mHSPC"
Video 4 - "ARASENS Trial- Darolutamide in mHSPC"
Video 3 - "Treatment Intensification in Metastatic Prostate Cancer"
Video 2 - "Treatment Options for mHSPC"
Related Content